First Regulatory Approval Granted for Oral Antiviral Favipiravir for Treatment of COVID-19 Patients Gained by GlenmarkA fast-tracked manufacturing and marketing approval for Favipiravir was granted to Glenmark Pharmaceuticals by the Drug Controller General of India (DCGI) for restricted emergency use in mild to moderate cases of COVID-19. With this approval, Glenmark’s branch FabiFlu becomes the first oral Favipiravir medication available in India for COVID-19 patients. The company has launched the prescription-based drug at a price of INR 103/tablet.  The drug has been indicated for treatment of mild to moderately sick patients along with diabetic or cardiovascular comorbidities, showing symptoms of COVID-19. The recommended dose suggested is- 1800 mg twice on the first day, followed by 800 mg twice a day up to day 14. The RNA-dependent RNA polymerase inhibitor, developed by Fujifilm Toyama Chemical was previously approved for treatment of Influenza virus infections in Japan since 2014

Quelle: First Regulatory Approval Granted for Oral Antiviral Favipiravir for Treatment of COVID-19 Patients Gained by Glenmark